Epiterna is a Swiss biotech start-up that has developed a high-throughput platform to evaluate drugs and assess their effect on healthy lifespan. Founded in 2022 by Kevin Perez and Alejandro Ocampo, the company emerged from stealth as it announced outside investment. CEO Alejandro Ocampo, who brings fifteen years of experience studying ageing, said the team aims to translate laboratory discoveries into longer, healthier lives for companion dogs, cats and people. Epiterna plans to start its first clinical trial for companion dogs in Europe in 2024 and intends to initiate clinical trials for people before launching its first products for companion animals. The company received an investment believed to be about €10 million from Prima Materia, the firm founded by Daniel Ek and Shakil Khan. Detailed financial terms and instruments were not disclosed in the announcement.

Total raised

$11M

Funding rounds

1

Latest round

Equity

Latest activity

Aug 2023